Furthermore, when CD8 T cells were depleted during FTY720 and Erb-sumIL2 treatment, the therapeutic effects of Erb-sumIL2 were abrogated and  the same results were observed from the MC38 tumor model (Fig. 4c). This evidence concerns the gene CD8A and neoplasm.